Lucid Diagnostics Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Lucid Diagnostics reported Q2 2026 revenue of $1.5 million (vs. $1.163M in Q2 2025) and processed 2,770 EsoGuard tests. The company secured its first laboratory benefit manager (LBM) coverage policy from Concert (acquired by Lyric), which has already been adopted by multiple health plans. Q2 GAAP net loss was $14.7M (including $3.0M preferred dividend); cash position was $33.4M as of June 30, 2026, down from $34.7M at year-end 2025.
Why this rating
Revenue growth (29% YoY) and first LBM coverage are modest positives, but company burns $14M+ quarterly against $33M cash. Relative to $82.7M market cap, progress is real but incremental; no near-term inflection visible.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.